Register Now - Beyond Recruitment: The Future of Patient Site Engagement in Oncology Clinical Trials
|Articles|June 18, 2014

Looking to History vs. Focusing on the Current Trial

Historical information and analytical foundations for RBM are important, but, in my view, RBM is about proactively managing each individual trial to quality and efficiency goals.

Editor’s Note: This is the second post in a three-part series. You can read the first post here, and the third post here.


Perhaps the BMS pilot project focused so intensely on gathering historical information as a basis for developing risk-based analytical assessments, KPIs and KRIs that the project ream had little opportunity to address process improvement, technology development and staff training and development. If so, this raises two questions:

  • Without process improvement, supporting technology and staff retraining, once the project succeeds in defining KPIs and KRIs, how will it be possible to utilize them in a manner that substantially improves trial management, execution and data quality?

  • Does overwhelming emphasis on the historical perspective obscure the paramount importance of developing KPIs and KRIs as management tools to address the unique operational issues of each individual trial, including issues that emerge only during execution of the current trial?

Historical information and analytical foundations for RBM are important, but, in my view, RBM is about proactively managing each individual trial to quality and efficiency goals.  Prospective considerations based on timely information are more important to RBM success than the historical record.  Effectively managing the current trial involves far more than having a central analytical staff identify KPIs and determine triggers for monitoring visits. Central staff should be managing the study in real time, continuously addressing issues in the field and resolving many issues without the need for site visits. Properly implemented, RBM is not a discrete activity but an integral component of proactive trial management.


[The concluding post in this three-part series will consider cost and quality implications of risk-based monitoring.]

This post first appeared on the Health Decisions blog, Trials Without Tribulations.


Related to this article

Closing the Community Access Gap: Q&A with Kent Thoelke, Paradigm Health
In this Q&A, Kent Thoelke, CEO of Paradigm Health, discusses why participation gaps in community and rural settings come down to both patient cost barriers and site infrastructure, how legacy workflows weigh on community clinics, and what policy and technology changes it would take to make clinical research a real care option for more patients.
© Grispb - © Grispb - stock.adobe.com
Mistral and OpenAI produced identical overall eligibility labels across 200 synthetic patient-study assessments, with criterion-level disagreements concentrated in inclusion criteria where models switch between “Uncertain” and “Not included” when records lack sufficient evidence, so model choice should be driven by deployment architecture, control, and cost rather than assumed interchangeability.
The Human Side of Clinical Trials: Before Burden Becomes Risk, Capturing Friction in Real Time
In Episode 4 of The Human Side of Clinical Trials, host Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., speaks with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about how capturing friction closer to the moment it happens can reveal unclear instructions, technology friction, and workarounds that retrospective surveys and debriefs tend to miss.